Toni Choueiri reports on the advanced renal cell carcinoma cohort of the phase 1/2 trial of MK-6482, a first-in-class inhibitor of hypoxia-inducible factor (HIF)-2α (2:36).
15-02-2020 | ASCO GU 2020 | Conference coverage | Video
15-02-2020 | ASCO GU 2020 | Conference coverage | Video
Toni Choueiri reports on the advanced renal cell carcinoma cohort of the phase 1/2 trial of MK-6482, a first-in-class inhibitor of hypoxia-inducible factor (HIF)-2α (2:36).